意領科技有限公司 Eieling Technology Ltd.

10/09/2026

Welcome, everyone, to the testing

大家好，
10月份脂肪肝及肝臟纖維化掃描檢測服務 (Liverscan)
日期如下：
22/10/2026 (星期四)
費用:HK$880
現正接受登記及報名，歡迎預約請致電 2890 1333 或 whatsapp 6848 0354

06/09/2026

Eieling Technology at GUTMeeting 2026 in Kuala Lumpur – advancing liver health solutions for the Southeast Asian market.

We are pleased to join our local partner at GUTMeeting 2026, working together to bring Liverscan® into clinical practice and healthcare services across Malaysia.

During the conference, Liverscan® received strong interest and positive feedback from local clinicians, highlighting its value in liver fibrosis and steatosis assessment. We also had the opportunity to engage in meaningful discussions with multiple specialists, gaining deeper insights into regional clinical needs and application scenarios.

Eieling Technology remains committed to driving innovation and delivering accurate, portable, and accessible liver health assessment tools for healthcare professionals worldwide.
🌐www.eieling.com
📧[email protected]



意領科技於吉隆坡參與 GUTMeeting 2026，深化東南亞臨床合作。

我們很高興與馬來西亞當地合作夥伴共同參與本屆 GUTMeeting 2026，攜手推動 Liverscan® 於當地醫療社群的臨床應用與服務落地。

展會期間，Liverscan® 獲得許多當地臨床醫師的關注與正面回饋，展現其在肝纖維化與脂肪肝定量評估上的臨床價值。我們亦與多位專科醫師進行深入交流，進一步了解區域內的臨床需求與應用場景。

意領科技將持續投入創新技術研發，致力為全球醫療專業人員提供精準、便攜且可及的肝臟健康評估工具。
🌐www.eieling.com
📧[email protected]

04/09/2026

肝臟健康在索馬里邁出新一步——Liverscan® 現已於摩加迪沙 Samakaal 醫院正式投入臨床應用。

在無創診斷工具仍屬匱乏的地區，我們欣見當地將 Liverscan® 引入臨床實踐。

Liverscan® 是一款無線掌上型瞬時彈性成像系統，結合以下核心技術：

實時 B 超影像引導、AI 輔助定位與品質控制、約一分鐘內同時輸出肝硬度值（LSM，kPa）與肝脂肪含量（MAP，dB/m）之定量結果

根據一項涵蓋 1,455 例的多中心臨床研究數據（Liver International, 2026）：

与活检对比，肝硬化檢測（F4）AUROC 達 0.97

脂肪肝檢測（≥S1）AUROC 達 0.92

對於管理慢性肝病、MASLD 或接受 GLP-1 治療患者的臨床醫生而言，一項便攜、可重複且客觀的評估工具，正在改變肝病隨訪管理的方式。
🌐www.eieling.com
📧[email protected]

A new step for liver health in Somalia – Liverscan® now in use at Samakaal Hospital, Mogadishu.

In a region where access to non‑invasive diagnostic tools remains limited, we are pleased to see our local partner, OOG BioSolutions, bring Liverscan® into clinical practice.

Liverscan® is a wireless, palm‑sized transient elastography system that combines:
Real‑time B‑mode ultrasound guidance 、AI‑assisted positioning and quality control 、Quantitative outputs liver stiffness (LSM, kPa) and fat content (MAP, dB/m) in approximately one minute

Clinical data from a 1,455‑case multi‑centre study (Liver International, 2026) show that：

vs biopsy， AUROC 0.97 for cirrhosis detection (F4) and 0.92 for steatosis detection (≥S1)

For clinicians managing chronic liver disease, MASLD, or patients on GLP‑1 therapy, having a portable, repeatable, and objective tool in the clinic changes the approach to follow‑up.
🌐www.eieling.com
📧[email protected]

28/08/2026

🔬 【臨床解讀】最新發表於《Liver International》(2026) 的前瞻性研究，評估了一款結合 AI 演算法、無線掌上型超音波與實時 B-mode 影像引導 的新一代瞬態彈性成像系統 Liverscan® 。

📌 主要結論：活檢對照： 在 138 例經肝活檢確診的患者 cohort 中，肝硬化（F4）的 AUROC 達到 0.97。MAP（多領域衰減參數）診斷脂肪肝（≥S1）的 AUROC 高達 0.92。

競品對比（Head-to-Head vs. FibroScan®）： 在 1,455 例大型配對 cohort 中，Liverscan® 與傳統 FibroScan® 展現出高度一致性（肝硬度 r=0.86；脂肪衰減參數 r=0.80）。

檢測次數簡化： 非劣效性分析顯示，在 B-mode 實時影像引導下，僅需 4 次有效測量 即可達到與傳統 10 次測量相同的診斷準確度。

💡 臨床與實務意義：

對患者： 檢查時間大幅縮短，且無線設計使檢查能延伸至門診、社區甚至床邊，大幅提升就醫便利性。

對醫生： 提供 B-mode 實時影像引導，避免盲測與誤採樣；AI 自動識別皮下脂肪厚度並切換模式，加上只需 4 次測量即可達到高診斷率，極大地優化了臨床工作流程。

🔬 Clinical Interpretation – A prospective study published in Liver International (2026) evaluated Liverscan, a next-generation transient elastography system integrating AI algorithms, a wireless handheld ultrasound probe, and real-time B-mode image guidance.

📌 Key Findings:

Biopsy-Controlled Validation: In a cohort of 138 patients confirmed by liver biopsy, the AUROC for cirrhosis (F4) reached 0.97. The MAP (Multi-domain Attenuation Parameter) achieved an AUROC of 0.92 for diagnosing hepatic steatosis (≥S1).

Head-to-Head vs. FibroScan®: In a large matched cohort of 1,455 patients, Liverscan® demonstrated high consistency with conventional FibroScan® (liver stiffness: r=0.86; fat attenuation parameter: r=0.80).

Simplified Measurement Protocol: A non-inferiority analysis demonstrated that, with real-time B-mode image guidance, only 4 valid measurements are required to achieve diagnostic accuracy equivalent to the conventional 10-measurement protocol.

💡 Clinical and Practical Implications:

For Patients: Examination time is significantly reduced. The wireless design enables testing to be extended to outpatient clinics, community settings, and even bedside, greatly improving patient convenience and access.

For Clinicians: Real-time B-mode image guidance prevents blind measurements and sampling errors. AI automatically identifies subcutaneous fat thickness and switches modes accordingly. With only 4 measurements needed to achieve high diagnostic accuracy, the clinical workflow is substantially streamlined and optimized.

26/08/2026

【減重藥時代，肝臟健康不能只靠體重計】

GLP-1減重藥解決了「減多少」，卻回答不了另一個關鍵問題：
❓ 體重降了，肝臟脂肪跟著降了嗎？

脂肪肝是「沈默的肝病」，不痛不癢，一旦發現往往已是中晚期。GLP-1用藥人群，恰恰是最需要FattaLab® 持續、定量、可追蹤肝臟脂肪變化的一群人。
FattaLab®
✅ 30秒定量 · 手持無線 · 無需空腹抽血
✅ 與MRI-PDFF金標準一致性 r=0.76（P < 0.001，n = 48）
✅ FDA 510(k) 獲批 · CES 2026 創新大獎

📌 这些品牌已先行驗證：

友邦保險（AIA） — 將肝臟定量篩查納入會員健康服務，打造差異化健康管理體驗
維特健靈（Vita Green） — 於門市推出「肝臟健康影像掃描服務」，香港零售保健首創
安利（Amway） — 讓營養品用戶看見肝臟健康的可量化改善
Swisse — 結合護肝營養與定量監測，於屈臣氏等零售渠道落地「吃+測」閉環
樂敦製藥（Rohto） — 將FattaLab®用於功能性食品與異位脂肪研究

同一項技術，被保險、零售、營養、製藥四大賽道同時選中——它已不是單一產品，而是一套可被複用的基礎設施。

📌 肝臟脂肪，看得見，才管得住。
📩 您所在的企業也想將肝臟健康監測納入服務或產品？
歡迎與我們聯繫，探索合作可能性。

📧 [email protected]
🌐 www.eieling.com
【In the Era of Weight-Loss Drugs, Liver Health Can't Be Measured by a Scale Alone】

GLP-1 drugs answer "how much weight was lost" — but they can't answer this critical question:
❓ Weight dropped — but did liver fat drop with it?

Fatty liver is the "silent liver disease" — no pain, no warning, often detected too late. GLP-1 users are exactly the population that most needs FattaLab® for continuous, quantitative, and trackable liver fat monitoring.

FattaLab®
✅ 30-second quantification · Handheld · Wireless · No fasting
✅ MRI-PDFF gold standard correlation: r=0.76 (P < 0.001, n=48)
✅ FDA 510(k) cleared · CES 2026 Innovation Award

📌 These brands have already validated this approach:

AIA— Integrating quantitative liver screening into member health services for differentiated health management
Vita Green — Launched "Liver Health Imaging Scan Service" in retail stores, a first in Hong Kong's retail healthcare sector
Amway— Enabling nutrition users to see quantifiable improvements in their liver health
Swisse— Combining liver health nutrition with quantitative monitoring, delivering a "consume + measure" closed loop at Watsons retail channels
Rohto Pharmaceutical — Deploying FattaLab® for functional food and ectopic fat research

When the same technology is adopted by insurance, retail, nutrition, and pharmaceuticals simultaneously, it is no longer just a product — it is a replicable infrastructure.

📌 What gets measured, gets managed.
📩 Is your company looking to integrate liver health monitoring into your services or products?
Reach out to us to explore partnership opportunities.


📧 [email protected]
🌐 www.eieling.com

18/08/2026

🇹🇭🤝🇨🇳 8月10日，泰國衛生部代表團到訪意領科技，雙方就肝病防控、高校科研合作、人才培養及全國性肝臟篩查等議題深入交流。

泰國為東南亞肝病高發國家，肝癌居癌症死因首位，每年逾2.6萬人死亡。44.6% 的泰國成年人患有脂肪肝，但僅 20% 高風險患者獲轉診專科，防控形勢嚴峻。

兩大旗艦產品 Liverscan® 與 FattaLab®，已實現從脂肪定量到纖維化評估的完整覆蓋，適合在基層醫療、社區及流動篩查中大規模部署。

泰國衛生部對意領科技的全鏈條解決方案給予高度評價，認為與該國基層肝病篩查體系建設高度契合。未來雙方將深化產學研協同，推動科研成果高效轉化為公共衛生應用，為區域肝病防控貢獻創新實踐。
🇹🇭🤝🇨🇳 On August 10, 2026, a delegation from the Thai Ministry of Health visited Eieling Technology for discussions on liver disease prevention, research collaboration, talent development, and national liver screening programs.

Its flagship products, Liverscan® and FattaLab®, cover the full spectrum from fat quantification to fibrosis assessment—ideal for deployment in primary care, community, and mobile screening settings.

Thailand faces a high liver disease burden: liver cancer is the #1 cancer killer, with 26,000+ deaths annually. 44.6% of Thai adults have MASLD, yet only 20% of high-risk patients are referred to specialists.

The Ministry praised Eieling's solutions as highly aligned with Thailand's grassroots screening infrastructure goals. Both sides will deepen industry-university-research collaboration to translate innovation into public health impact across the region.
Learn more：www.eieling.com
[email protected]

16/08/2026

【GLP-1 熱潮下，你忽略了肝臟脂肪嗎？】💡

體重下降 ≠ 肝臟脂肪同步改善！傳統檢測不是太貴（MRI）、太主觀（傳統超音波），就是具侵入性（肝穿刺）。

FattaLab 專為追蹤而生，讓肝脂肪檢測像量血壓一樣簡單：

⚡ 極致輕量：僅 120g 掌上設計，比手機還輕
⏱️ 極速操作：AI 輔助 3D 定位，30 秒完成評估（零門檻）
📊 精準定量：提供可追蹤的 dB/m 數字，告別模糊的「輕/中/重」
📉 一致追蹤：為每次回診提供客觀量化數據，療效不再憑感覺

🏆 CES 2026 數字健康創新獎 · FDA 510(k) 許可

📩 體重管理診所/醫療機構/藥局欢迎私訊諮詢，瞭解合作方案！
www.eieling.com
[email protected]
+852 55621051
Riding the GLP-1 Wave? Don't Ignore Your Liver Fat! 💡

Weight loss doesn't always equal liver fat reduction. Traditional tests are either subjective (ultrasound), expensive (MRI), or invasive (biopsy).

FattaLab makes liver fat monitoring as simple as checking blood pressure:

⚡ Ultra-Lightweight: Only 120g handheld design—lighter than a smartphone
⏱️ 30-Second Scan: AI-guided 3D positioning, zero ultrasound experience needed
📊 Precise Quantification: Delivers trackable dB/m numerical data, not vague estimates
📉 Built for Repeat Visits: Consistent quantitative metrics to track real progress
FattaLab®’s attenuation measurement is validated against Liverscan® MAP in a prospective head-to-head pilot

🏆 CES 2026 Innovation Award (Digital Health) · FDA 510(k) Cleared

📩 Partner with us to upgrade your weight clinic or healthcare service—DM us today!
www.eieling.com
[email protected]
+852 55621051

14/08/2026

讓大規模社區肝臟篩檢，從理想變成現實！💡

傳統篩檢面臨設備笨重、操作門檻高、耗時長等痛點？Liverscan 專為社區現場打造，全面打破檢測壁壘：

⚡ 無線輕巧：隨時隨地，即開即用 🎯 B 超導引：視覺化定位，非專業聲學人員也能精準操作 🚀 效率提升 2 倍：僅需 4 次有效測量（傳統需 10 次），每小時篩檢量大幅提升！ 📊 一次掃描，雙重數據：同時獲取肝臟硬度与脂肪定量

實測已成功找出多位無症狀的高風險患者（F3 嚴重纖維化）。

📩 想瞭解 Liverscan 如何提升您的社區健康專案效率？立即私訊我們！

[email protected]
+852 55621051
www.eieling.com

Turning "Every Community Can Screen" into Reality. 💡

Heavy equipment, high operator dependency, and slow screening times shouldn't limit liver care. Liverscan is built for real-world community settings:

⚡ Truly Portable: Wireless handheld design, anywhere, anytime 🎯 B‑mode ultrasound guidance: Visual targeting reduces operator dependency for consistent accuracy 🚀 2x Faster Throughput: Only 4 valid measurements needed vs. 10 conventionally 📊 Dual-Output: Simultaneous liver stiffness & fat quantification in a single scan

Proven in community screenings to catch hidden risks early (up to F3 fibrosis).

📩 Want to boost your screening capacity? DM us today for details or a demo!
[email protected]
+852 55621051
www.eieling.com

07/08/2026

改變肝臟健康評估的方式——現在就加入我們

肝病常被稱為「沉默的殺手」，全球約三分之一的成年人受到代謝相關脂肪性肝病（MASLD）的影響。

Liverscan® 重新定義了肝臟評估

📌 全球首款搭載即時 B 超影像引導的無線掌上型瞬態彈性成像系統

📌 僅需 4 次有效測量即可獲得可靠結果——效率為傳統設備的 2 倍

📌 單次檢測同步輸出肝硬度（LSM） 與脂肪定量（MAP） 兩項指標

📌 四組 AI 深度學習模型即時輔助，確保診斷級一致性

📌 臨床驗證：與肝穿刺活檢對照，肝硬化（F4）檢測 AUROC 達 0.97，脂肪肝（≥S1）篩查 AUROC 達 0.92

📌 已獲美國 FDA 510(k) 及中國 NMPA 三類醫療器械認證

從專科門診到社區篩查，從專業醫療到基層保健——Liverscan® 讓精準肝臟評估不再受限於大型醫院。

讓肝臟健康評估，像量血壓一樣簡單。

🔗 了解更多：eieling.com

Changing the Way Liver Health Is Assessed — Join Us

Liver disease is often called the "silent killer," affecting approximately 1 in 3 adults globally with MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease).

Liverscan® Redefines Liver Assessment

📌 World's first wireless, palm-sized transient elastography system with real-time B-mode ultrasound guidance

📌 Reliable results from just 4 valid measurements — 2x the efficiency of conventional workflow

📌 Simultaneously measures Liver Stiffness (LSM) and Fat Quantification (MAP) in a single exam

📌 Powered by 4 AI deep learning models running in real time for diagnostic-grade consistency

📌 Clinically validated against liver biopsy gold standard: AUROC 0.97 for cirrhosis (F4) detection, AUROC 0.92 for steatosis (≥S1) screening

📌 FDA 510(k) cleared in the U.S. and NMPA Class III approved in China

From specialist clinics to community screening, from hospitals to point-of-care — Liverscan® makes accurate liver assessment accessible anywhere.

Making liver health assessment as simple as checking blood pressure.

🔗 Learn more: eieling.com

05/08/2026

意領科技攜手VCP，共創東南亞肝臟健康新篇章🌏

2026年7月28日，我們正式與 VCP簽署合作協議。

此次合作體現了雙方共同致力於變革東南亞肝臟健康的承諾。我們將意領先進的早期篩檢和診斷解決方案與VCP在越南成熟的醫藥及分銷網絡相結合，旨在建立覆蓋肝臟健康全生命週期的創新商業模式。

我們期待與VCP攜手合作，為該地區帶來世界一流的肝臟護理解決方案。

了解更多關於我們對全球肝臟健康的承諾：www.eieling.com

[email protected]

Eieling Technology Partners with VCP to Advance Liver Health in Southeast Asia 🌏

On July 28, 2026, we officially signed a cooperation agreement with VCP.

This partnership is a shared commitment to transforming liver healthcare in Southeast Asia. By integrating Eieling Technology’s advanced early screening and diagnostic solutions with VCP’s established pharmaceutical and distribution network in Vietnam, we aim to build an innovative business model that covers the entire lifecycle of liver health.

We are looking forward to collaborating with VCP to bring world-class liver care solutions to the region.

Learn more about our commitment to global liver health: www.eieling.com
[email protected]